By participating in the 2024 National Immunoglobulin (Ig) Treatment Survey, you can share your experiences with intravenous, subcutaneous, and intramuscular Ig replacement therapy. Your firsthand experiences will help us further define the characteristics of patients who receive Ig therapy and provide valuable information to healthcare and research communities that can improve the quality of care of individuals living with PI.
Questions? Contact the Immune Deficiency Foundations Vice President of Research, Christopher Scalchunes, at cscalchunes@primaryimmune.org.